Applied Therapeutics, Inc. announced successful completion of a recent pre-New Drug Application (?NDA?) meeting with the Food and Drug Administration (FDA) regarding its govorestat (AT-007) Galactosemia program. Based on discussions with the FDA, the Company believes they are aligned with the FDA and plans to submit an NDA for govorestat (AT-007) for the treatment of Galactosemia in the fourth quarter of this year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.4 USD | -5.17% | -6.58% | +31.34% |
May. 09 | Applied Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 09 | Earnings Flash (APLT) APPLIED THERAPEUTICS Posts Q1 Revenue $190,000 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.34% | 503M | |
+7.52% | 113B | |
+11.38% | 106B | |
+0.84% | 22.27B | |
-12.64% | 22.22B | |
-4.59% | 19.43B | |
-37.85% | 17.87B | |
-8.58% | 17.24B | |
+7.77% | 14.29B | |
+37.41% | 12.52B |
- Stock Market
- Equities
- APLT Stock
- News Applied Therapeutics, Inc.
- Applied Therapeutics, Inc. Announces Successful Pre-Nda Meeting with the Fda and Confirms Plans to Submit Nda for Govorestat (At-007) for Treatment of Classic Galactosemia to Fda in Fourth Quarter 2023